A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.

ABSTRACT:

Introduction

Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting.

Methods

We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative).

Results

Both treatments showed similar efficacy relative to the MG-ADL sca

SUBMITTER: Pane C 

PROVIDER: S-EPMC11377599 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature